Recombinant Rhesus macaque TNFRSF18 protein, Fc-tagged

• Cat.No.: TNFRSF18-1480R
• Product Overview: Recombinant Rhesus macaque TNFRSF18 protein(Gln26-Glu161), fused with Fc tag, was expressed in HEK293.

Specification

• Source: HEK293
• Species: Rhesus macaque
• Tag: Fc
• Form: Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5.
• Molecular Mass: This protein carries a human IgG1 Fc tag at the C-terminus.The protein has a calculated MW of 41.3 kDa. As a result of glycosylation, the protein migrates as 48 kDa under reducing (R) condition, and 85 kDa under non-reducing (NR) condition (SDS-PAGE).
• Proteinlength: Gln26-Glu161
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: For long term, the product should be stored at lyophilized state at -20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after at:
  -20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• Protein length: Gln26-Glu161

Reviews

12/20/2021

This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

03/05/2020

Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

10/01/2017

The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

Q&As

What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment?

Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

Are there any approved TNFRSF18-targeted therapies for cancer treatment?

As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

Are there potential side effects associated with TNFRSF18-targeted therapies?

Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

How can TNFRSF18-targeted therapies potentially improve cancer outcomes?

TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

Can TNFRSF18-targeted therapies be used in combination with other immunotherapies?

Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.